12 Results

People

  1. Hamlin
    Hamlin
  2. Intlekofer
    Intlekofer
  3. Kumar
    Kumar
  4. Noy
    Noy
  5. Palomba
    Palomba
  6. Zelenetz
    Zelenetz
  7. Caron
    Caron
  8. Horwitz
    Horwitz
  9. Moskowitz
    Moskowitz
  10. Matasar
    Matasar

Groups

  1. Bone Marrow Transplant (12)
  2. Center for Hematologic Malignancies (12)
  3. Department of Medicine (12)
  4. GSK Faculty (12)
  5. Hematologic Malignancies Research (12)
  6. Hematologic Malignancies, Division of (12)
  7. Human Oncology and Pathogenesis Program (12)
  8. Lymphoma (12)
  9. Survivorship Research (12)
  10. Population Sciences Research Program (11)
  1. "Hematologic Malignancies Research"
  2. "Center for Hematologic Malignancies"
  3. "Bone Marrow Transplant"
  4. "Andrew Zelenetz"
Formats
  1. Meeting Abstract (11)
  2. Journal Article (1)
Groups
  1. Bone Marrow Transplant (12)
  2. Center for Hematologic Malignancies (12)
  3. Department of Medicine (12)
  4. GSK Faculty (12)
  5. Hematologic Malignancies Research (12)
  6. Hematologic Malignancies, Division of (12)

More Groups

People
  1. Andrew Intlekofer (12)
  2. Andrew Zelenetz (12)
  3. Anita Kumar (12)
  4. Ariela Noy (12)
  5. Maria Palomba (12)
  6. Paul Hamlin (12)

More People

Years
  1. 2023 (2)
  2. 2022 (1)
  3. 2021 (1)
  4. 2020 (1)
  5. 2019 (2)
  6. 2017 (2)

More Years

Publications
  1. Blood (10)
  2. Hematological Oncology (1)
  3. Journal of Clinical Oncology (1)
Publishers
  1. American Society of Hematology (10)
  2. American Society of Clinical Oncology (1)
  3. Wiley Blackwell (1)

Results (12)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Responses and outcomes after second-line therapy in transplant-eligible patients with DLBCL relapse over 1 year after first-line therapy
    Meeting Abstract

    Qualls, D. A.; Shah, G. L.; Shouval, R.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Distinct patterns of CD4+and CD8+ T-cell clonal expansion enable broad clinical responses to pembrolizumab + GVD in patients with relapsed Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Rahman, J.; Ganesan, N.; Shah, G. L.; Noy, A.; Schoder, H.; Yahalom, J.; Kumar, A.; Falchi, L.; Hamlin, P. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Retrospective analysis of gemcitabine and oxaliplatin (GemOx)-based treatment in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Meeting Abstract

    Schade, J. R.; Kim, C.; Drill, E.; Qiu, A.; Batlevi, C. L.; Caron, P.; Colbourn, D. S.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Impact of PET staging of follicular lymphoma on treatment outcomes and prognosis
    Meeting Abstract

    Alperovich, A.; Batlevi, C. L.; Intlekofer, A. M.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, M. L.; Moskowitz, A. J.; Gerecitano, J.; Hamlin, P. A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Time from prognosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma
    Meeting Abstract

    Soumerai, J. D.; Ni, A.; Batlevi, C.; Alperovich, A.; Bantilan, K. S.; Palomba, M.; Gerecitano, J. F.; Noy, A.; Hamlin, P.; Moskowitz, C. H.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Outcomes of follicular lymphoma patients by dynamic FLIPI at diagnosis and initial treatment in the post-rituximab era
    Meeting Abstract

    Batlevi, C.; Alperovich, A.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save